Analysis Suggests Oral Steroids Better Than Intravenous Ones for Treating Relapsing MS
DECEMBER 4, 2017 Ashraf Malhas, PhD Oral steroids may be cheaper, more convenient and less invasive alternatives than intravenous…
Ocrelizumab More Cost-Effective Than Interferon
J Med Econ; 2017 Oct; Yang, Duchesneau, et al November 21, 2017 Ocrelizumab is more cost-effective than subcutaneous (SC) interferon…
Stuart Schlossman
Anti-Inflammatory Drug May Offer Benefit in Progressive MS
Ibudilast seems to diminish brain volume loss by Kristina Fiore, Deputy Managing Editor, MedPage TodayOctober 29, 2017 PARIS – An old compound…
Stuart Schlossman
EVOLVE-MS-1 Interim Trial Data Shows Alkermes Therapy Safe for Treating Relapsing MS
Preliminary data from the Phase 3 EVOLVE-MS-1 trial shows that ALKS 8700 — an investigative therapy developed by Alkermes to treat relapsing forms of…
Stuart Schlossman
Two Studies Show IL-35 Protein’s Potential to Curb Inflammation in Autoimmune Diseases
October 24, 2017 An immune signaling protein called interleukin-35 has anti-inflammatory properties that scientists might harness to develop a therapy…
Stuart Schlossman
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
OCT 28, 2017 PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on…
Stuart Schlossman
New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis
· Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity…
Stuart Schlossman
MS could be reversed with existing allergy drug
By Tim Newman – Published Friday 13 October 2017 A drug used to treat allergies has been shown to increase nerve speed…
Stuart Schlossman
Ocrelizumab Offers Greater Value Than Interferon
J Med Econ; 2017 Oct; Frasco, Shih, Incerti, et al October 17, 2017 Ocrelizumab provides greater value to relapsing forms…
Stuart Schlossman
Study uncovers potential risks of common MS treatment
n one of the most comprehensive studies to date, University of British Columbia researchers found an increased risk of events…
Stuart Schlossman
